{"slug":"china","tag":"china","variants":["china"],"description":"Companies, products, trials, people and institutions based in or centred on China.","count":121,"kinds":{"company":42,"person":18,"drug":32,"institution":11,"trial":18},"related":[{"slug":"registry-only","tag":"registry-only","shared":15},{"slug":"nmpa-approved","tag":"nmpa-approved","shared":12},{"slug":"bispecific","tag":"bispecific","shared":1},{"slug":"clinician-scientist","tag":"clinician-scientist","shared":1},{"slug":"leadership","tag":"leadership","shared":1},{"slug":"liver-cancer","tag":"liver cancer","shared":1},{"slug":"lung","tag":"lung","shared":1},{"slug":"surgical-oncology","tag":"surgical oncology","shared":1}],"records":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/","tldr":"Jiangsu Hengrui is China's largest oncology pharma, maker of pyrotinib and the HER2 ADC trastuzumab rezetecan, and one of the biggest out-licensers of Chinese assets."},{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/","tldr":"Chinese biosimilar and biologics company whose PD-1 antibody serplulimab is approved in China and Europe for small-cell lung cancer."},{"id":"huang-xiaojun","kind":"person","name":"Xiaojun Huang","route":"/people/huang-xiaojun/","tldr":"Xiaojun Huang built the Beijing Protocol for stem cell transplants from half-matched family donors, which means almost every Chinese leukaemia patient can now find a donor."},{"id":"chen-saijuan","kind":"person","name":"Saijuan Chen","route":"/people/chen-saijuan/","tldr":"Saijuan Chen helped turn acute promyelocytic leukaemia from one of the deadliest leukaemias into one of the most curable, by showing how retinoic acid and arsenic act and combining them."},{"id":"chen-zhu","kind":"person","name":"Zhu Chen","route":"/people/chen-zhu/","tldr":"Zhu Chen, a leukaemia scientist who became China's health minister, co-developed the retinoic acid plus arsenic treatment that cures most acute promyelocytic leukaemia and then reformed the health system that pays for it."},{"id":"qin-shukui","kind":"person","name":"Shukui Qin","route":"/people/qin-shukui/","tldr":"Shukui Qin has led most of the Chinese liver cancer trials of the past decade, including the ones that put camrelizumab plus rivoceranib and donafenib into first-line use."},{"id":"fan-jia","kind":"person","name":"Jia Fan","route":"/people/fan-jia/","tldr":"Jia Fan leads one of the world's busiest liver cancer surgery and transplant programmes and the proteogenomic studies that mapped how hepatitis B-related liver cancer differs at the molecular level."},{"id":"xu-jianming","kind":"person","name":"Jianming Xu","route":"/people/xu-jianming/","tldr":"Jianming Xu led the Chinese stomach cancer trials of sintilimab, the ADC disitamab vedotin and other domestic drugs, in the country with the most stomach cancer patients."},{"id":"cheng-ying","kind":"person","name":"Ying Cheng","route":"/people/cheng-ying/","tldr":"Ying Cheng has led most of the Chinese small cell lung cancer immunotherapy trials, including ASTRUM-005 and CAPSTONE-1."},{"id":"guo-jun","kind":"person","name":"Jun Guo","route":"/people/guo-jun/","tldr":"Jun Guo built China's melanoma programme around the acral and mucosal subtypes common in Asia, and led the trials that made toripalimab the first domestic PD-1 antibody approved."},{"id":"li-zonghai","kind":"person","name":"Zonghai Li","route":"/people/li-zonghai/","tldr":"Zonghai Li moved CAR-T therapy from blood cancers into stomach cancer, founding CARsgen and developing satri-cel, the first CAR-T approved for a solid tumour."},{"id":"oyler-john","kind":"person","name":"John Oyler","route":"/people/oyler-john/","tldr":"John Oyler co-founded BeiGene in Beijing in 2010 and built it into the first China-born biotech to run global trials, win FDA approvals and out-sell Western rivals with zanubrutinib."},{"id":"xia-michelle","kind":"person","name":"Michelle Xia (Xia Yu)","route":"/people/xia-michelle/","tldr":"Michelle Xia founded Akeso, the Zhongshan company whose bispecific antibody ivonescimab was the first drug to beat pembrolizumab in a head-to-head trial."},{"id":"yu-michael","kind":"person","name":"Michael Yu (Yu De-Chao)","route":"/people/yu-michael/","tldr":"Michael Yu founded Innovent in Suzhou in 2011 and made sintilimab one of China's best-selling cancer drugs before turning the company into a supplier of new medicines to Roche and Takeda."},{"id":"sun-piaoyang","kind":"person","name":"Piaoyang Sun","route":"/people/sun-piaoyang/","tldr":"Piaoyang Sun turned a small Lianyungang generics factory into Hengrui, China's largest originator drug company and the source of camrelizumab, apatinib and a dozen other approved cancer drugs."},{"id":"du-samantha","kind":"person","name":"Samantha Du (Du Ying)","route":"/people/du-samantha/","tldr":"Samantha Du founded Zai Lab in 2014 to license Western cancer drugs for China, bringing niraparib, zanidatamab and Tumour Treating Fields to Chinese patients years earlier than they would otherwise have arrived."},{"id":"li-ge","kind":"person","name":"Ge Li","route":"/people/li-ge/","tldr":"Ge Li founded WuXi AppTec in Shanghai in 2000 and built the contract research and manufacturing network that much of the world's cancer pipeline now depends on."},{"id":"su-weiguo","kind":"person","name":"Weiguo Su","route":"/people/su-weiguo/","tldr":"Weiguo Su led the Shanghai chemistry that produced fruquintinib, savolitinib and surufatinib, three Chinese-discovered cancer pills approved at home and, for fruquintinib, in the US."},{"id":"zhang-fangliang","kind":"person","name":"Fangliang (Frank) Zhang","route":"/people/zhang-fangliang/","tldr":"Frank Zhang founded GenScript and its cell therapy spin-out Legend Biotech, whose Nanjing team invented the myeloma CAR-T that became Carvykti."},{"id":"qing-zhou","kind":"person","name":"Qing Zhou","route":"/people/qing-zhou/","tldr":"Chinese thoracic oncologist behind HARMONi-2, where the PD-1/VEGF bispecific ivonescimab beat pembrolizumab head to head."},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/","status":"approved","tldr":"Sintilimab is Innovent's PD-1 antibody, approved in China since 2018 for Hodgkin lymphoma and then, on the ORIENT trials, for first-line lung, liver, oesophageal and stomach cancer. In 2022 the FDA rejected its lung cancer application because a China-only trial against chemotherapy did not fit US practice, defining the agency's stance on single-country data."},{"id":"sugemalimab","kind":"drug","name":"Sugemalimab","route":"/drugs/sugemalimab/","status":"approved","tldr":"Sugemalimab is CStone's PD-L1 antibody, approved in China for first-line lung cancer with chemotherapy and after chemoradiotherapy in stage III disease, and the first China-developed PD-L1 antibody to win European approval."},{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/","status":"approved","tldr":"Adebrelimab is Hengrui's PD-L1 antibody, approved in China for first-line extensive-stage small cell lung cancer on the CAPSTONE-1 trial."},{"id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/","status":"approved","tldr":"Envafolimab is the first PD-L1 antibody given as a quick injection under the skin rather than an infusion, approved in China for advanced tumours with mismatch-repair deficiency."},{"id":"relmacabtagene-autoleucel","kind":"drug","name":"Relmacabtagene autoleucel","route":"/drugs/relmacabtagene-autoleucel/","status":"approved","tldr":"Relma-cel was the first CAR-T therapy developed and made in China to be approved, for large B-cell lymphoma that has come back after two treatments."},{"id":"equecabtagene-autoleucel","kind":"drug","name":"Equecabtagene autoleucel","route":"/drugs/equecabtagene-autoleucel/","status":"approved","tldr":"Equecabtagene autoleucel is a BCMA CAR-T from IASO Bio and Innovent, approved in China in June 2023 for multiple myeloma that has returned after at least three lines of treatment. In the FUMANBA-1 trial about 96% of infused patients responded, most with deep minimal-residual-disease-negative remissions and few severe cytokine release reactions; it competes with cilta-cel and zevor-cel in China."},{"id":"zevorcabtagene-autoleucel","kind":"drug","name":"Zevorcabtagene autoleucel","route":"/drugs/zevorcabtagene-autoleucel/","status":"approved","tldr":"Zevor-cel is CARsgen's myeloma CAR-T, approved in China in 2024 for patients whose disease has come back after three or more treatments."},{"id":"inaticabtagene-autoleucel","kind":"drug","name":"Inaticabtagene autoleucel","route":"/drugs/inaticabtagene-autoleucel/","status":"approved","tldr":"Inati-cel is a Chinese CAR-T for adults with acute lymphoblastic leukaemia that has come back or stopped responding, approved in 2023."},{"id":"fulzerasib","kind":"drug","name":"Fulzerasib","route":"/drugs/fulzerasib/","status":"approved","tldr":"Fulzerasib was the first KRAS G12C-blocking pill approved in China, for lung cancers carrying that mutation after earlier treatment."},{"id":"garsorasib","kind":"drug","name":"Garsorasib","route":"/drugs/garsorasib/","status":"approved","tldr":"Garsorasib is InventisBio's KRAS G12C-blocking pill, approved in China in 2024 for previously treated lung cancer with that mutation."},{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/","status":"approved","tldr":"Furmonertinib is a Chinese lung cancer pill of the same class as osimertinib, which more than doubled the time before cancer grew compared with gefitinib in the FURLONG trial."},{"id":"aumolertinib","kind":"drug","name":"Aumolertinib","route":"/drugs/aumolertinib/","status":"approved","tldr":"Aumolertinib is Hansoh's third-generation lung cancer pill, the first China-developed drug of its class, approved for first-line EGFR-mutant lung cancer on the AENEAS trial."},{"id":"icotinib","kind":"drug","name":"Icotinib","route":"/drugs/icotinib/","status":"approved","tldr":"Icotinib, approved in 2011, was the first cancer drug invented and developed in China, and it showed that a domestic lung cancer pill could match a Western one head to head."},{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/","status":"approved","tldr":"Savolitinib is a Chinese-discovered pill that blocks the MET growth signal, approved in China for lung cancers with a MET exon 14 mutation and being tested worldwide with osimertinib."},{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/","status":"approved","tldr":"Anlotinib is one of the most used cancer pills in China, first approved for lung cancer after other treatments have failed and then for several rarer tumours."},{"id":"rivoceranib","kind":"drug","name":"Rivoceranib (apatinib)","route":"/drugs/rivoceranib/","status":"approved","tldr":"Apatinib, sold as rivoceranib outside China, was the first pill of its kind approved for stomach cancer and is now the partner of camrelizumab in first-line liver cancer."},{"id":"donafenib","kind":"drug","name":"Donafenib","route":"/drugs/donafenib/","status":"approved","tldr":"Donafenib is a Chinese redesign of sorafenib that lived longer than the original in a head-to-head liver cancer trial and is approved in China as a first-line option."},{"id":"orelabrutinib","kind":"drug","name":"Orelabrutinib","route":"/drugs/orelabrutinib/","status":"approved","tldr":"Orelabrutinib is InnoCare's BTK-blocking pill for chronic lymphocytic leukaemia and mantle cell lymphoma, approved in China in 2020."},{"id":"dalpiciclib","kind":"drug","name":"Dalpiciclib","route":"/drugs/dalpiciclib/","status":"approved","tldr":"Dalpiciclib is Hengrui's CDK4/6 inhibitor, the first China-developed drug of the class, approved for hormone-driven advanced breast cancer on the DAWNA trials."},{"id":"tucidinostat","kind":"drug","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/","status":"approved","tldr":"Chidamide, approved in 2014, was the first epigenetic cancer drug invented in China and the first oral drug of its kind anywhere, used for T-cell lymphoma and, with hormone therapy, for breast cancer."},{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/","tldr":"Innovent makes sintilimab, China's best-selling PD-1 antibody, and has become a source of next-generation assets for Roche and Takeda."},{"id":"junshi","kind":"company","name":"Shanghai Junshi Biosciences","route":"/companies/junshi/","tldr":"Junshi developed toripalimab, the first Chinese PD-1 antibody approved in China (2018) and the first approved by the FDA (2023, nasopharyngeal cancer)."},{"id":"zai-lab","kind":"company","name":"Zai Lab","route":"/companies/zai-lab/","tldr":"Zai Lab is the in-licensing pioneer that brings Western cancer drugs to China (niraparib, zanidatamab, repotrectinib, Tumour Treating Fields) and now exports its own bispecific and ADC assets."},{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/","tldr":"Hutchmed discovered fruquintinib, the first Chinese cancer drug approved by the FDA for a common cancer, and savolitinib, its MET inhibitor partnered with AstraZeneca."},{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/","tldr":"CSPC is a large Chinese pharma whose cancer business rests on albumin-bound paclitaxel and liposomal doxorubicin generics, an ADC pipeline and a growing list of licences to Western companies."},{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/","tldr":"Sino Biopharm, through Chia Tai Tianqing, sells anlotinib, one of China's biggest cancer drugs, and acquired LaNova Medicines to add bispecific antibodies and ADCs."},{"id":"wuxi-apptec","kind":"company","name":"WuXi AppTec","route":"/companies/wuxi-apptec/","tldr":"WuXi AppTec is the contract research and manufacturing giant that makes small molecules, including ADC payloads and linkers, for much of the global cancer pipeline, and the target of the US BIOSECURE Act."},{"id":"wuxi-biologics","kind":"company","name":"WuXi Biologics","route":"/companies/wuxi-biologics/","tldr":"WuXi Biologics develops and manufactures antibodies for hundreds of clients worldwide, and its WuXi XDC unit is the largest contract maker of antibody-drug conjugates."},{"id":"jw-therapeutics","kind":"company","name":"JW Therapeutics","route":"/companies/jw-therapeutics/","tldr":"JW Therapeutics, a Juno and WuXi AppTec joint venture, made relma-cel, the first CAR-T developed and manufactured in China to be approved."},{"id":"iaso-bio","kind":"company","name":"IASO Biotherapeutics","route":"/companies/iaso-bio/","tldr":"IASO Bio developed eque-cel, the fully human BCMA CAR-T for myeloma approved in China in 2023 and partnered with Innovent."},{"id":"cstone","kind":"company","name":"CStone Pharmaceuticals","route":"/companies/cstone/","tldr":"CStone developed sugemalimab, the first Chinese PD-L1 antibody approved in Europe, and brought pralsetinib, avapritinib and ivosidenib to China."},{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/","tldr":"Allist is the single-product lung cancer company behind furmonertinib, China's other third-generation EGFR pill, partnered with ArriVent for the rest of the world."},{"id":"genfleet","kind":"company","name":"GenFleet Therapeutics","route":"/companies/genfleet/","tldr":"GenFleet discovered fulzerasib, the first KRAS G12C inhibitor approved in China, and licensed it to Innovent for the Chinese market."},{"id":"inventisbio","kind":"company","name":"InventisBio","route":"/companies/inventisbio/","tldr":"InventisBio developed garsorasib, one of the two KRAS G12C pills approved in China in 2024, and the third-generation EGFR inhibitor befotertinib."},{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/","tldr":"Alphamab developed envafolimab, the first subcutaneous PD-L1 antibody approved anywhere, and the HER2 bispecific ADC JSKN003."},{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","route":"/companies/zelgen/","tldr":"Zelgen developed donafenib, the deuterated sorafenib that beat the original in first-line liver cancer and was approved in China in 2021."},{"id":"innocare","kind":"company","name":"InnoCare Pharma","route":"/companies/innocare/","tldr":"InnoCare developed orelabrutinib, a selective BTK-blocking pill approved in China for chronic lymphocytic leukaemia and mantle cell and marginal zone lymphomas."},{"id":"betta","kind":"company","name":"Betta Pharmaceuticals","route":"/companies/betta/","tldr":"Betta made icotinib, the first cancer drug invented in China, and later ensartinib, the first Chinese ALK inhibitor to win FDA approval."},{"id":"chipscreen","kind":"company","name":"Chipscreen Biosciences","route":"/companies/chipscreen/","tldr":"Chipscreen discovered chidamide (tucidinostat), the first original epigenetic cancer drug from China, approved in 2014 and later in Japan."},{"id":"ncc-china","kind":"institution","name":"National Cancer Center of China","route":"/institutions/ncc-china/","tldr":"The National Cancer Center is the body that counts China's cancers, sets national screening and quality programmes and publishes the country's official cancer statistics."},{"id":"nhsa","kind":"institution","name":"National Healthcare Security Administration","route":"/institutions/nhsa/","tldr":"The NHSA runs China's public health insurance and negotiates once a year which new cancer drugs are reimbursed, and at what price, through the National Reimbursement Drug List."},{"id":"caca","kind":"institution","name":"China Anti-Cancer Association","route":"/institutions/caca/","tldr":"The China Anti-Cancer Association is the country's largest cancer society, publishing the CACA guidelines that aim to reflect Chinese patients and Chinese drugs rather than imported recommendations."},{"id":"ctong","kind":"institution","name":"Chinese Thoracic Oncology Group","route":"/institutions/ctong/","tldr":"CTONG is the cooperative group of Chinese lung cancer trialists, founded by Yi-Long Wu, whose trials on EGFR-targeted pills before and after surgery changed practice worldwide."},{"id":"pku-peoples-hospital","kind":"institution","name":"Peking University People's Hospital","route":"/institutions/pku-peoples-hospital/","tldr":"Peking University People's Hospital is the world's largest haploidentical stem cell transplant centre and the home of the Beijing Protocol that lets almost any patient find a donor."},{"id":"cams-hematology","kind":"institution","name":"Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences","route":"/institutions/cams-hematology/","tldr":"China's national blood disease hospital in Tianjin is where the CD19 binder behind the CAR-T inati-cel was made; it runs large leukaemia and myelodysplastic syndrome registries and early-phase trials of domestic bispecifics and cell therapies."},{"id":"renji-hospital","kind":"institution","name":"Renji Hospital, Shanghai Jiao Tong University","route":"/institutions/renji-hospital/","tldr":"Renji Hospital and the Shanghai Cancer Institute on its campus are where CARsgen's solid-tumour CAR-T work began, including the Claudin 18.2 CAR-T satri-cel for stomach cancer."},{"id":"jilin-cancer-hospital","kind":"institution","name":"Jilin Cancer Hospital","route":"/institutions/jilin-cancer-hospital/","tldr":"Jilin Cancer Hospital in Changchun is the centre that led China's small cell lung cancer immunotherapy trials, including ASTRUM-005 and CAPSTONE-1."},{"id":"jiangsu-cancer-hospital","kind":"institution","name":"Jiangsu Cancer Hospital","route":"/institutions/jiangsu-cancer-hospital/","tldr":"Jiangsu Cancer Hospital in Nanjing is a large provincial cancer centre and a frequent lead site for Chinese oesophageal, lung and gastric cancer trials."},{"id":"chongqing-university-cancer-hospital","kind":"institution","name":"Chongqing University Cancer Hospital","route":"/institutions/chongqing-university-cancer-hospital/","tldr":"Chongqing University Cancer Hospital is the main cancer centre for south-west China's largest city and a growing site for domestic trials."},{"id":"sichuan-cancer-hospital","kind":"institution","name":"Sichuan Cancer Hospital","route":"/institutions/sichuan-cancer-hospital/","tldr":"Sichuan Cancer Hospital in Chengdu is a large provincial cancer centre known for oesophageal and head and neck cancer radiotherapy and a partner of the city's ADC companies."},{"id":"orient-11","kind":"trial","name":"ORIENT-11","route":"/trials/orient-11/","status":"positive","tldr":"The trial that made sintilimab a first-line lung cancer treatment in China, and the one the FDA later refused to accept as evidence for US patients."},{"id":"orient-32","kind":"trial","name":"ORIENT-32","route":"/trials/orient-32/","status":"positive","tldr":"A Chinese trial showing that a PD-1 antibody plus a bevacizumab copy extends life in liver cancer, mirroring the global IMbrave150 result in a hepatitis B population."},{"id":"orient-16","kind":"trial","name":"ORIENT-16","route":"/trials/orient-16/","status":"positive","tldr":"The Chinese stomach cancer trial that showed adding sintilimab to chemotherapy helps patients live longer, especially when the tumour expresses PD-L1."},{"id":"rationale-302","kind":"trial","name":"RATIONALE-302","route":"/trials/rationale-302/","status":"positive","tldr":"The global trial in which tislelizumab beat chemotherapy for oesophageal cancer that had progressed after first treatment, which carried it to approval in the US, Europe and Japan."},{"id":"camel","kind":"trial","name":"CameL","route":"/trials/camel/","status":"positive","tldr":"The trial that made camrelizumab a first-line lung cancer option in China, one of several domestic PD-1 antibodies to reproduce the KEYNOTE-189 result."},{"id":"jupiter-06","kind":"trial","name":"JUPITER-06","route":"/trials/jupiter-06/","status":"positive","tldr":"The trial that added toripalimab to chemotherapy for oesophageal cancer in China and showed a survival gain regardless of PD-L1 level."},{"id":"harmoni-a","kind":"trial","name":"HARMONi-A","route":"/trials/harmoni-a/","status":"positive","tldr":"The first phase 3 win for ivonescimab, in lung cancer that has stopped responding to EGFR pills, and the basis of its first approval in China."},{"id":"capstone-1","kind":"trial","name":"CAPSTONE-1","route":"/trials/capstone-1/","status":"positive","tldr":"The trial that added Hengrui's PD-L1 antibody adebrelimab to chemotherapy for small cell lung cancer, with one of the larger survival gains seen in that disease."},{"id":"gemstone-302","kind":"trial","name":"GEMSTONE-302","route":"/trials/gemstone-302/","status":"positive","tldr":"The trial behind sugemalimab's approval in China and later Europe, showing a PD-L1 antibody plus chemotherapy delays progression in both main types of lung cancer."},{"id":"furlong","kind":"trial","name":"FURLONG","route":"/trials/furlong/","status":"positive","tldr":"The head-to-head trial in which furmonertinib nearly doubled the time before lung cancer grew compared with gefitinib, mirroring FLAURA with a Chinese drug."},{"id":"aeneas","kind":"trial","name":"AENEAS","route":"/trials/aeneas/","status":"positive","tldr":"The trial that showed Hansoh's aumolertinib roughly doubles progression-free survival compared with gefitinib in EGFR-mutant lung cancer."},{"id":"alter-0303","kind":"trial","name":"ALTER 0303","route":"/trials/alter-0303/","status":"positive","tldr":"The trial that showed anlotinib helps patients with lung cancer live longer after other treatments have failed, the basis of one of China's most used cancer pills."},{"id":"legend-2","kind":"trial","name":"LEGEND-2","route":"/trials/legend-2/","status":"positive","tldr":"The small Chinese trial whose startling response rates at ASCO 2017 drew Johnson and Johnson to Legend Biotech and became the myeloma CAR-T Carvykti."},{"id":"fumanba-1","kind":"trial","name":"FUMANBA-1","route":"/trials/fumanba-1/","status":"positive","tldr":"The single-arm trial that won eque-cel its approval in China, with almost every patient responding and most reaching deep remissions."},{"id":"lummicar-1","kind":"trial","name":"LUMMICAR STUDY 1","route":"/trials/lummicar-1/","status":"positive","tldr":"The Chinese trial behind zevor-cel's approval for multiple myeloma, showing deep and lasting responses with a fully human BCMA CAR-T."},{"id":"reliance","kind":"trial","name":"RELIANCE","route":"/trials/reliance/","status":"positive","tldr":"The trial that made relma-cel the first CAR-T developed and manufactured in China to be approved, with three quarters of patients responding."},{"id":"dawna-1","kind":"trial","name":"DAWNA-1","route":"/trials/dawna-1/","status":"positive","tldr":"The trial that made dalpiciclib the first Chinese CDK4/6 inhibitor approved, more than doubling the time before breast cancer grew when added to fulvestrant."},{"id":"zgdh3","kind":"trial","name":"ZGDH3 (donafenib vs sorafenib)","route":"/trials/zgdh3/","status":"positive","tldr":"The first trial in which a new pill beat sorafenib on survival in liver cancer, with a Chinese deuterated redesign of sorafenib itself."},{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","route":"/companies/hansoh-pharma/","tldr":"Hansoh is a Chinese pharmaceutical group whose EGFR inhibitor aumolertinib (Ameile in China, Aumseqa in the EU) became the first China-originated lung cancer pill authorised by the European Commission in 2026."},{"id":"biostar-pharmaceuticals","kind":"company","name":"Biostar Pharmaceuticals","route":"/companies/biostar-pharmaceuticals/","tldr":"Biostar Pharmaceuticals in Chengdu developed utidelone, the epothilone chemotherapy approved in China in 2021 for advanced breast cancer."},{"id":"3sbio","kind":"company","name":"3SBio","route":"/companies/3sbio/","tldr":"3SBio is a Shenyang biologics company whose HER2 antibody inetetamab was approved in China in 2020 for HER2-positive metastatic breast cancer."},{"id":"juventas-cell-therapy","kind":"company","name":"Juventas Cell Therapy","route":"/companies/juventas-cell-therapy/","tldr":"Juventas Cell Therapy in Tianjin developed inaticabtagene autoleucel, the first CAR-T approved in China for leukaemia (2023)."},{"id":"shanghai-yingli","kind":"company","name":"Shanghai Yingli Pharmaceutical","route":"/companies/shanghai-yingli/","tldr":"Shanghai Yingli Pharmaceutical developed linperlisib, the PI3K-delta inhibitor approved in China in 2022 for relapsed follicular lymphoma."},{"id":"shanghai-sunway-biotech","kind":"company","name":"Shanghai Sunway Biotech","route":"/companies/shanghai-sunway-biotech/","tldr":"Shanghai Sunway Biotech makes Oncorine (H101), the oncolytic adenovirus approved in China in 2005, the first oncolytic virus approved anywhere."},{"id":"chengdu-zenitar-biomedical-technology","kind":"company","name":"Chengdu Zenitar Biomedical Technology","route":"/companies/chengdu-zenitar-biomedical-technology/","tldr":"Chengdu Zenitar Biomedical Technology is a Chinese developer in Chengdu that sponsors 6 registered cancer trials of Purinostat and Purinostat Mesylate."},{"id":"jacobio-pharmaceuticals","kind":"company","name":"Jacobio Pharmaceuticals","route":"/companies/jacobio-pharmaceuticals/","tldr":"Jacobio Pharmaceuticals is a Chinese developer in Beijing that sponsors 6 registered cancer trials of JAB-30355 and JAB-2485."},{"id":"beijing-konruns-pharmaceutical","kind":"company","name":"Beijing Konruns Pharmaceutical","route":"/companies/beijing-konruns-pharmaceutical/","tldr":"Beijing Konruns Pharmaceutical is a Chinese developer in Beijing that sponsors 5 registered cancer trials of KC1036 and S-1."},{"id":"beijing-mabworks-biotech","kind":"company","name":"Beijing Mabworks Biotech","route":"/companies/beijing-mabworks-biotech/","tldr":"Beijing Mabworks Biotech is a Chinese developer in Beijing that sponsors 4 registered cancer trials of MBS314 and MBS303."},{"id":"binhui-biopharmaceutical","kind":"company","name":"Binhui Biopharmaceutical","route":"/companies/binhui-biopharmaceutical/","tldr":"Binhui Biopharmaceutical is a Chinese developer in Wuhan that sponsors 4 registered cancer trials of OH2 and HX008."},{"id":"beijing-pearl-biotechnology-limited-liability-company","kind":"company","name":"Beijing Pearl Biotechnology Limited Liability Company","route":"/companies/beijing-pearl-biotechnology-limited-liability-company/","tldr":"Beijing Pearl Biotechnology Limited Liability Company is a Chinese developer in Beijing that sponsors 3 registered cancer trials of PLB1001 and Temozolomide."},{"id":"beijing-scitech-mq-pharmaceuticals","kind":"company","name":"Beijing Scitech-Mq Pharmaceuticals","route":"/companies/beijing-scitech-mq-pharmaceuticals/","tldr":"Beijing Scitech-Mq Pharmaceuticals is a Chinese developer in Beijing that sponsors 3 registered cancer trials of ST-1898."},{"id":"immvira-pharma","kind":"company","name":"ImmVira Pharma","route":"/companies/immvira-pharma/","tldr":"ImmVira Pharma is a Chinese developer in Shenzhen that sponsors 3 registered cancer trials of Herpes Virus C5252 and T3011."},{"id":"shandong-new-time-pharmaceutical","kind":"company","name":"Shandong New Time Pharmaceutical","route":"/companies/shandong-new-time-pharmaceutical/","tldr":"Shandong New Time Pharmaceutical is a Chinese developer in Shandong that sponsors 3 registered cancer trials of F182112 and F182112 single-agent."},{"id":"beijing-gene-key-life-technology","kind":"company","name":"Beijing Gene Key Life Technology","route":"/companies/beijing-gene-key-life-technology/","tldr":"Beijing Gene Key Life Technology is a Chinese developer in Beijing that sponsors 2 registered cancer trials of GKL-006."},{"id":"beijing-tide-pharmaceutical","kind":"company","name":"Beijing Tide Pharmaceutical","route":"/companies/beijing-tide-pharmaceutical/","tldr":"Beijing Tide Pharmaceutical is a Chinese developer in Beijing that sponsors 2 registered cancer trials of TCC1727."},{"id":"henan-genuine-biotech","kind":"company","name":"Henan Genuine Biotech","route":"/companies/henan-genuine-biotech/","tldr":"Henan Genuine Biotech is a Chinese developer in Henan that sponsors 2 registered cancer trials of GEN-725 and Dositinib."},{"id":"nanjing-immunophage-biotech","kind":"company","name":"Nanjing Immunophage Biotech","route":"/companies/nanjing-immunophage-biotech/","tldr":"Nanjing Immunophage Biotech is a Chinese developer in Nanjing that sponsors 2 registered cancer trials of IPG1094 and IPG7236."},{"id":"tj-biopharma","kind":"company","name":"TJ Biopharma","route":"/companies/tj-biopharma/","tldr":"TJ Biopharma is a Chinese developer in Shanghai that sponsors 2 registered cancer trials of Uliledlimab and Sintilimab."},{"id":"zhuhai-yufan-biotechnologies","kind":"company","name":"Zhuhai Yufan Biotechnologies","route":"/companies/zhuhai-yufan-biotechnologies/","tldr":"Zhuhai Yufan Biotechnologies is a Chinese developer in Zhuhai that sponsors 2 registered cancer trials of PRJ1-3024."},{"id":"benmelstobart","kind":"drug","name":"Benmelstobart","route":"/drugs/benmelstobart/","status":"approved","tldr":"Benmelstobart is Chia Tai Tianqing's PD-L1 antibody, approved in China in 2024 for extensive-stage small-cell lung cancer in combination with anlotinib and chemotherapy."},{"id":"iruplinalkib","kind":"drug","name":"Iruplinalkib","route":"/drugs/iruplinalkib/","status":"approved","tldr":"Iruplinalkib is Qilu Pharmaceutical's second-generation ALK inhibitor, approved in China in 2023 for ALK-positive non-small-cell lung cancer after crizotinib and in 2024 as first-line treatment."},{"id":"flumatinib","kind":"drug","name":"Flumatinib","route":"/drugs/flumatinib/","status":"approved","tldr":"Flumatinib is Hansoh Pharma's second-generation BCR-ABL inhibitor, approved in China in 2019 for newly diagnosed chronic-phase chronic myeloid leukaemia."},{"id":"utidelone","kind":"drug","name":"Utidelone","route":"/drugs/utidelone/","status":"approved","tldr":"Utidelone is Biostar Pharmaceuticals' epothilone chemotherapy, approved in China in 2021 with capecitabine for advanced breast cancer after anthracyclines and taxanes."},{"id":"inetetamab","kind":"drug","name":"Inetetamab","route":"/drugs/inetetamab/","status":"approved","tldr":"Inetetamab is 3SBio's HER2 antibody, approved in China in 2020 with vinorelbine for HER2-positive metastatic breast cancer."},{"id":"linperlisib","kind":"drug","name":"Linperlisib","route":"/drugs/linperlisib/","status":"approved","tldr":"Linperlisib is Shanghai Yingli's PI3K-delta inhibitor, approved in China in 2022 for relapsed or refractory follicular lymphoma after two or more lines."},{"id":"surufatinib","kind":"drug","name":"Surufatinib","route":"/drugs/surufatinib/","status":"approved","tldr":"Surufatinib is HUTCHMED's angio-immuno kinase inhibitor, approved in China in 2020 for non-pancreatic and in 2021 for pancreatic neuroendocrine tumours."},{"id":"recombinant-human-endostatin","kind":"drug","name":"Recombinant human endostatin","route":"/drugs/recombinant-human-endostatin/","status":"approved","tldr":"Endostar is Simcere's recombinant endostatin, approved in China in 2005 with chemotherapy for advanced non-small-cell lung cancer, one of the first angiogenesis inhibitors approved anywhere."},{"id":"h101-oncolytic-adenovirus","kind":"drug","name":"H101 oncolytic adenovirus","route":"/drugs/h101-oncolytic-adenovirus/","status":"approved","tldr":"Oncorine is Shanghai Sunway Biotech's oncolytic adenovirus, approved in China in 2005 for nasopharyngeal carcinoma with chemotherapy, the first oncolytic virus approved anywhere in the world."},{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/","status":"approved","tldr":"QL1706 is Qilu Pharmaceutical's PD-1 plus CTLA-4 antibody mixture, approved in China in 2024 for recurrent or metastatic cervical cancer after platinum chemotherapy."},{"id":"mecapegfilgrastim","kind":"drug","name":"Mecapegfilgrastim","route":"/drugs/mecapegfilgrastim/","status":"approved","tldr":"Mecapegfilgrastim is Hengrui's long-acting G-CSF, approved in China in 2018 to prevent chemotherapy-induced neutropenia."},{"id":"vorolanib","kind":"drug","name":"Vorolanib","route":"/drugs/vorolanib/","status":"approved","tldr":"Vorolanib is Betta Pharmaceuticals' oral VEGFR and PDGFR inhibitor, approved in China in 2023 with everolimus for advanced kidney cancer after a first kinase inhibitor has failed."}]}